Teva Inks Texas Opioids Settlement And Eyes J&J’s Nationwide ‘Formula’

Israeli Giant Spells Out ~$3bn Nationwide Settlement Ambition; Wants Deal In 2022

 
• By Dean Rudge

Teva CEO Kåre Schultz has spoken at great length of the firm’s current standing with opioid-related matters, days after it reached a deal valued at $225m to resolve claims in the state of Texas. A nationwide deal is still top of the Israeli firm’s agenda, with a rough estimate of $3bn-$4bn suggested.

3D rendering conceptual image of dollars, symbolizing the rising prices - Illustration
Teva wants existing shareholders to benefit once legal issues are settled • Source: Shutterstock: elsar

More from Legal & IP

More from Generics Bulletin